Verification of endometrial tissue biomarkers previously discovered using mass spectrometry-based proteomics by means of immunohistochemistry in a tissue microarray format

Journal of Proteome Research

Volumn 6, Issue 7, 2007, Pages 2648-2655

  Dubé, Valerie ^a   Grigull, Jörg ^b   DeSouza, Leroi V ^b   Ghanny, Shaun ^c   Colgan, Terence J ^a,c   Romaschin, Alexander D ^c,d   Michael Siu, K W ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b YORK UNIVERSITY   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Biomarkers; Chaperonin 10; Endometrial carcinoma; Immunohistochemistry; Microarray; Pyruvate kinase M2; Tissue; Tissue proteomics; Verification

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CHAPERONIN; PYRUVATE KINASE M2; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; TISSUE MICROARRAY;

CHROMATOGRAPHY, LIQUID; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; PROTEOMICS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 34547141212     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr070087o     Document Type: Article

References (51)

1. Li, C.; Hong, Y.; Tan, Y.-X.; Zhou, H.; Ai, J.-H.; Li, S.-J.; Zhang, L.; Xia, Q.-C. Wu, J.-R.; Wang, H.-Y.; Zeng, R. Accurate qualitative and quantitative proteomic analysis of clinical hepatocellular carcinoma using laser capture microdissection coupled with isotope-coded affinity tag and two-dimensional liquid chromatography mass spectrometry. Mol. Cell. Proteomics 2004, 3 399-409.
2. Veenstra, T. D.; Conrads, T. P.; Hood, B. L.; Avellino, A.; Ellenbogen, R.; Morrison, R. Biomarkers: mining the biofluid proteome. Mol. Cell. Proteomics 2005, 4, 409-418.
3. Caldwell, R. L.; Caprioli, R. M. Tissue profiling by mass spectrometry. Mol. Cell. Proteomics 2005; 4, 394-401.
4. Maruvada, P.; Wang, W.; Wagner, P. D.; Srivastava, S.; Biomarkers in molecular medicine: cancer detection and diagnosis. Biomarkers Cancer Res. 2005, 38, 9-15.
5. Chaurand, P.; Schwartz, S. A.; Capriole, R. M. Assessing protein patterns in disease using imaging mass spectrometry. J. Prot. Res. 2004, 3, 245-252.
6. Ransohoff, D. F. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 2004, 4, 309-314.
7. Wilkins, M.; Appel, R.; Van Eyk, J.; Chung, M.; Görg, A.; Hecker, M.; Huber, L.; Langen, H.; Link, A.; Paik, Y.; Patterson, S.; Pennington, S.; Rabilloud, T.; Simpson, R.; Weiss, W.; Dunn, M. Guidelines for the next 10 years of proteomics. Proteomics 2006, 6, 4-8.
8. Cregger, M.; Berger, A.; Rimm, D. Immunohistochemistry and quantitative analysis of protein expression. Arch. Pathol. Lab. Med. 2006, 130, 1026-1030.
9. DeSouza, L.; Diehl, G.; Rodrigues, M.; Guo, J.; Romaschin, A.; Colgan, T.; Siu, K. W. M. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J. Prot. Res. 2005, 4, 377-386.
10. Kononen, J.; Bubendorf, L.; Kallioniemi, A.; Barlund, M.; Schraml, P.; Leighton, S.; Torhorst, J.; Mihatsch, M.; Sauter, G.; Kallioniemi, O. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998, 4, 844-847.
11. Eguiluz, C.; Viguera, E.; Millan, L.; Perez, J. Multitissue array review: a chonological description of tissue array techniques applications and procedures. Path. Res. Pract. 2006, 202, 561-568.
12. Packeisen, J.; Buerger, H.; Krech, R.; Boecker, W. Tissue microarrays: a new approach for quality control in immunohistochemistry. J. Clin. Pathol. 2002, 55, 613-615.
13. Packeisen, J.; Korsching, E.; Herbst, H.; Boecker, W.; Buerger, H. Demystified ... tissue microarray technology. J. Clin. Pathol. 2003, 56, 198-204.
14. Simon, R.; Sauter, G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp. Hematol. 2002, 30, 1365-1372.
15. Torhorst, J.; Bucher, C.; Kononen, J.; Haas, P.; Zuber, M.; Kochli, O.; Mross, F.; Dieterich, H.; Moch, H.; Mihatsch, M.; Kallioniemi, O.; Sauter, G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am. J. Pathol. 2001, 159, 2249-2256.
16. Guo, J.; Colgan, T.; DeSouza, L.; Rodriguez, M.; Romaschin, A.; Siu, K. W. M. Direct analysis of laser capture microdissected endometrial carcinoma and epithelium by MALDI mass spectrometry. Rapid Commun. Mass Spectrom. 2005, 19, 2762-2766.
17. Yang, E.; Guo, J.; Diehl, G.; DeSouza, L.; Rodriguez, M.; Romaschin, A.; Colgan, T.; Siu, K. W. M. Protein expression profiling of endometrial malignancies reveals a new tumor marker: chaperonin 10. J. Proteome Res. 2004, 3, 636-643.
18. Guo, J.; Yang, E.; DeSouza, L.; Diehl, G.; Rodriguez, M.; Romaschin, A.; Colgan, T.; Siu, K. W. M. A strategy for high-resolution protein identification in surface-enhanced laser desorption/ionization mass spectrometry: calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma. Proteomics 2005, 5, 1-14.
19. Ariztia, E. V.; Lee, C. J.; Gogoi, R.; Fishman, D. A. The tumor microenvironment: key to early detection. Crit. Rev. Clin. Lab. Sci. 2006, 43, 393-425.
20. Allred, D.; Clark, G.; Elledge, R.; Fuqua, S.; Brown, R.; Chamness, G.; Osborne, C.; McGuire, W. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. 1993, 85, 200-206.
21. Allred, D.; Harvey, J.; Berardo, M.; Clark, G. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 1998, 11, 155-168.
22. Harvey, J.; Clark, G.; Osborne, C.; Allred, D. Estrogen receptor status by immunohsitochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999, 17, 1474-1481.
23. Hastie, T.; Tibshirani, R.; Friedman, J. The Elements of Statistical Learning; Springer: New York, 2001.
24. Pepe, M. The Statistical Evaluation of Medical Tests for Classification and Prediction; Oxford University Press: Oxford, 2003.
25. Simon, R.; Korn, E.; McShane, L.; Radmacher, M.; Wright, G.; Zhao, Y. Design and Analysis of DNA Microarray Investigations; Springer: New York, 2004.
26. DeSouza, L.V.; Grigull, J.; Ghanny, S.; Dubé, V.; Romaschin, A. D.; Colgan, T. J.; Siu, K. W. M. Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol. Cell. Proteomics [Online early access]. Published Online: March 19, 2007. http://www.mcponline. org/cgi/content/abstract/M600378-MCP200v1.
27. Meyer, A.; Gillespie, J.; Walther, D.; Millet, I.; Doniach, S.; Frydman, J. Closing the folding chamber of the eukaryotic chaperonin requires the transition state of ATP hydrolysis. Cell 2003, 113, 369-381.
28. Raspopov, S.; El-Farawamy, A.; Thomson, B.; Siu, K. W. M. Infrared multiphoton dissociation in quadrupole time-of-flight mass spectrometry to-down characterization of proteins. Anal. Chem. 2006, 78, 4572-4577.
29. Noonan, F.; Halliday, W.; Morton, H.; Clunie, G. Early pregnancy factor is immunosuppressive. Nature 1979, 278, 649-651.
30. Quinn, K.; Morton, H. Effect of monoclonal antibodies to early pregnancy factor (EPF) on the in vivo growth of transplantable murine tumours. Cancer Immunol. Immunother. 1992, 34, 265-271.
31. Quinn, K.; Athanasis-Plastis, S.; Wong, T-Y.; Rolfe, B.; Cavanagh, A.; Morton, H. Monoclonal antibodies to early pregnancy factor perturb tumour cell growth. Clin. Exp. Immunol. 1990, 80, 100-108.
32. Akyol, S.; Gercel-Taylor, C.; Reynolds, L.; Taylor, D. HSP-10 in ovarian cancer: expression and suppression of T-cell signaling. Gynecol. Oncol. 2006, 101, 481-86.
33. Cappello, F.; Bellafiore, M.; David, S.; Anzalone, R.; Zummo, G. Ten kilodalton heat shock protein (HSP10) is overexpressed during carcinogenesis of large bowel and uterine exocervix. Cancer Lett. 2003, 196, 35-41.
34. Somodevilla-Torres, M.; Hillyard, N.; Morton, H.; Alewood, D.; Halliday, J.; Alewood, P.; Vesey, D.; Walsh, M.; Cavanagh, A. Preparation and characterization of polyclonal antibodies against human chaperonin 10. Cell Stress Chaperones 2000, 5, 14-20.
35. Eigenbrodt, E.; Reinacher, M.; Scheefers-Borchel, U.; Scheefers, H.; Friis, R. Double role of pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells. Crit. Rev. Oncog. 1992, 3, 91-115.
36. Gumi'nska, M.; Ignacak, J.; Ķedryna, T.; Stachurska, B. Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells. Acta Biochim. Pol. 1997, 44, 711-724.
37. Hacker, H.; Steinberg, P.; Bannasch, P. Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/dl-ethionine-supplemented diet. Carcinogenesis 1998, 19, 99-107.
38. Eigenbrodt, E.; Gerbracht, U.; Mazurek, S.; et al. Carbohydrate Metabolism and Neoplasia: New Perspective for Diagnosis and Therapy, Academic Press: San Diego, CA, 1994, 311-385.
39. Noguchi, T.; Inoue, H.; Tanaka, T. The M1 and M2 type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA slicing. J. Biol. Chem. 1986, 261, 13807-13812.
40. Mazurek, S.; Boschek, C.; Eigenbrodt, E. The role of phosphometabolites in cell proliferation, energy metabolism and tumor therapy. Biomembrane 1997, 29, 315-330.
41. Mazurek, S.; Eigenbrodt, E. The tumor metabolome. Anticancer Res. 2003, 23, 1149-1154.
42. Ashizawa, K.; Willingham, M.; Liang, C.; Cheng, S. In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtypeM2 by glucose is mediated by fructose 1,6 biophosphate. J. Biol. Chem. 1991, 266, 16842-16846.
43. Dombrauckas, J.; Santarsiero, B.; Mesecar, A. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44, 9417-9429.
44. Yamada, K.; Noguchi, T. Alteration of isozyme gene expression during cell differentiation and oncogenesis. Nippon Rinsho 1995, 53, 1112-1118.
45. Mazurek, S.; Boschek, B.; Hugo, F.; Eigenbrodt, E. Pyruvate kinase M2 and its role in tumor growth and spreading. Sem. Cancer Biol. 2005, 15, 300-308.
46. Shneider, J.; Neu, K.; Grimm, H.; Velcovsky, H.; Weisse, G.; Eigenbrodt, E. Tumour M2 pyruvate kinase in lung cancer patients: immunohistochemical detection and disease monitoring. Anticancer Res. 2002, 22, 311-318.
47. Presek, P.; Reinacher, M.; Eigenbrodt, E. Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett. 1988, 242, 194-198.
48. Mazurek, S.; Zweschke, W.; Jansen-Dürr, P.; Eigenbrodt, E. Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic enzyme complex. Biochem. J. 2001, 356, 247-256.
49. Ahmed, A.; Dew, T.; Papadopoulos, A.; Devaja, O.; Lawton, F.; Raju, K.; Sherwood, R. M2-PK as a novel marker in ovarian cancer, a prospective cohort study. Int. J. Gynecol. Ca 2006, 16 (S3), 624-694.
50. Chiriboga, L.; Osman, I.; Mikhail, C.; Lau, C. Tissue microarrays, tread carefully (letter). Lab. Invest. 2004, 84, 1677.
51. Mirlacher, M.; Kasper, M.; Storz, M.; Knecht, Y.; Durmuller, U.; Simon, R.; Mihatsch, M.; Sauter, G. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod. Pathol. 2004, 17, 1414-1420.